Studieprotocol
Download
Flowchart
Follow-up schema
| Inclusie | Dag 1 | Week 2 | Week 4 | Week 8 | Week 12 | Maand 6 | |
|---|---|---|---|---|---|---|---|
| Baseline | |||||||
| In- en exclusiecriteria | X | ||||||
| Baseline gegevens | X | ||||||
| Behandeling | |||||||
| TXA of placebo | X | X | X | ||||
| Primaire uitkomstmaat | |||||||
| 1. Operatie voor cSDH? | X | X | X | X | X | ||
| Secundaire uitkomstmaten | |||||||
| 2. cSDH volume | X | X | X | X | |||
| 3. mNIHSS | X | X | X | X | |||
| 4. Valincidenten | X | X | X | X | |||
| 5. MOCA | X | X | X | X | |||
| 6a. Barthel | X | X | X | ||||
| 6b. Lawton-Brody | X | X | X | ||||
| 7. mRS | X | X | X | ||||
| 8a. SF-36 | X | X | X | ||||
| 8b. EQ-5D | X | X | X | ||||
| 9. Mortaliteit | X | X | X | X | |||
| 10a. iMCQ | X | X | X | X | |||
| 10b. iPCQ | X | X | X | X | |||
| Overig | |||||||
| Evaluatie wilsbekwaamheid | X | X | X | X | X | ||
| (S)AE's | X | X | X | X | X | ||
Inclusies
0
554
AMC: 225,
VUmc: 5,
MUMC: 20,
Tergooi: 7,
NWZ: 18,
Isala: 20,
VWB: 1,
Zuyderland: 12,
HMC: 1,
Radboud: 7,
MST: 5,
Gelre: 2,
EMC: 8,
CWZ: 0,
UMCG: 1,
UMCU: 2
Update: 01 Nov 2025
Contact
Financiers
Deelnemende centra
